4Teen4s DPP3 predicts burn mortality
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
S-Protein: Glycosylation pattern revealed
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Bone Therapeutics bags 11m
Belgian Bone Therapeutics SA has secured 11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
Bayer, Novartis, and Trump convicted by Nature
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.
Drug from worms dampens autoimmune response
German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.
COVID-19: Novartis starts study on hyped malaria drug
Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
COVID 19: Halix ready for vaccine production
Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .